Clinical Trial Update: A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ABP 938 and aflibercept (Eylea) in participants with chorioretinal vascular disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chorioretinal Vascular Disease

Drugs mentioned

• ABP 938 (aflibercept biosimilar)
• Aflibercept (Aflibercept)

Snippet

Sponsor: Amgen | Conditions: Chorioretinal Vascular Disease | Phase 3 | Status: COMPLETED | Results posted: 2025-02-14